Upon searching for products in women’s health applications, the results are staggeringly limited. Although, as a Western society, we have made strides in product development addressing women’s specific needs, admittedly, we have a ways to go.
Let’s take into account that 75-90% of the woman population in North America are currently in the reproductive through menopausal (peri- through post-) stages of life where the largest occurrences of vaginal imbalance take place. When we take a look at the future there are 1.2 billion women globally that will enter perimenopause or menopause by 2030. 85% of those women will experience symptoms that significantly impact their lives.
What are the Concerns?
Vaginal health can range from varying dryness concerns, which the majority of products on the market currently address, to conditions such as bacterial vaginosis, yeast infections, and vaginal atrophy. Access to products to treat these symptoms is important because almost a quarter of women surveyed (via an anonymous private online survey) in North America of different age ranges and education levels have admitted to utilizing at-home remedies or products not intended for such use. This has the potential to lead to further, preventable health complications.
With the current destigmatization of women’s reproductive and sexual health, it is imperative to invest in developments tailored to women’s needs now. Women’s purchasing of hygiene and treatment products is based on access, convenience, discretion, and effectiveness. You have the opportunity to take treatment and comfort to a new level with ovule applications, as they offer targeted delivery, higher concentration capabilities, faster relief, less filler, reduced risk of systemic side effects, a wider consumer base, and improved treatment compliance.
Simple Effective Solutions
Our offering of hard fats for ovule and suppository applications from IOI Oleochemical are unique materials, without direct competitive countertypes. Based entirely on sustainable sources of vegetable origin, they also provide peace of mind through product stewardship and safety. They are the first choice for vaginal and rectal forms that require better wetting of mucous membranes, enhanced dispersibility and absorption promotion.
WITEPSOL® S hard fats contain a non-ionic ethoxylated emulsifier (Cetostearyl alcohol), non-compendial, which enables emulsion formation when aqueous to semi-solid or ethanolic extract actives that are not soluble in hard fats are part of the finished formulation.
Benefits of Vaginal/Rectal Drug Delivery:
• Localized and systemic drug delivery
• Avoidance of First-Pass Metabolism
• Fast on-set of drug release
• Reduced Systemic side-effects
• Robust & simple formulation concepts, only small number of excipients required
The Witepsol S solutions are offered in 3 grades for your formulation needs.
